glp-1 dual agonist Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Machine learning designs new GCGR/GLP-1R

This is what the BNF said Thank you for your email to BNF Publications

However, it is noteworthy that current evidence supporting this mechanism primarily comes from in vitro chondrocyte models or rodent OA animal models, with relatively limited direct validation in human cartilage tissue

Kang YA, Choi HR, Na JI, Huh CH, Kim MJ, Youn SW, Kim KH, Park KC

Chlorambucil is an effective alkylating agent used in cancer treatment, targeting DNA replication and inducing apoptosis

About the Ontario Health Technology Assessment Series To conduct its comprehensive analyses, Evidence Development and Standards and its research partners review the available scientific literature, making every effort to consider all relevant national and international research

Abstract The GLP-1 receptor, one of the most successful drug targets for the treatment of type 2 diabetes and obesity, is known to engage multiple intracellular signaling proteins